Trial · NCT00430040
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
NCT00430040, Phase 4, Terminated, University at Buffalo; results first posted 2024-04-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. Trials, record NCT00430040. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00430040
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
- NCT number
- NCT00430040
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 14 participants, actual
- Lead sponsor
- University at Buffalo
- Conditions
- Diabetes Mellitus, Type 2, Hypertension
- Interventions
- Carvedilol Controlled Release (CR), lisinopril
- First posted
- 2007-02-01
- Last updated
- 2024-04-16
- Results first posted
- 2024-04-16
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Brachial Artery Vascular Reactivity | 6 months | Percent change from baseline in Brachial artery vascular reactivity at 6 months calculated as: (brachial reactivity at 6 months-brachial reactivity at 0 months)/brachial reactivity at 0 month \*100 |
| Secondary | Change in Oxidative Stress in Mononuclear Cells (MNC) | 6 months | Percent change from baseline in Reactive Oxygen species (ROS) generation in MNC at 6 months calculated as: (ROS at 6 months-ROS at 0 months)/ROS at 0 month \*100 |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Brachial Artery Vascular Reactivity | 6 months | percentage of change | MEAN | |
| SECONDARY | Change in Oxidative Stress in Mononuclear Cells (MNC) | 6 months | percentage of change | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Brachial Artery Vascular Reactivity | Carvedilol | 28 | Standard Error 20 | percentage of change | |
| Change in Brachial Artery Vascular Reactivity | Lisinopril | 19 | Standard Error 17 | percentage of change | |
| Change in Oxidative Stress in Mononuclear Cells (MNC) | Carvedilol | -15 | Standard Error 9 | percentage of change | |
| Change in Oxidative Stress in Mononuclear Cells (MNC) | Lisinopril | -10 | Standard Error 11 | percentage of change |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Carvedilol | 7 | |
| Overall Study | STARTED | Lisinopril | 7 | |
| Overall Study | COMPLETED | Carvedilol | 5 | |
| Overall Study | COMPLETED | Lisinopril | 6 | |
| Overall Study | NOT COMPLETED | Carvedilol | 2 | |
| Overall Study | NOT COMPLETED | Lisinopril | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Carvedilol | 0 | 7 |
| Total, all-cause mortality | Lisinopril | 0 | 7 |
| Total, other adverse events | Carvedilol | 0 | 7 |
| Total, other adverse events | Lisinopril | 0 | 7 |
| Total, serious adverse events | Carvedilol | 0 | 7 |
| Total, serious adverse events | Lisinopril | 0 | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Carvedilol vs Lisinopril: deaths from any cause | Trial comparisons |
| Carvedilol vs Lisinopril: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00430040
GET https://conductscience.org/api/trials/v1/NCT00430040/registered